[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$f4nu5lF87-KCrVv7xh_rYifnVZJzwpgLrWt-IoxJzQzo":8,"$fr1V4n2vwfmQlat8wSBvqkbqnsByN6En--CIy5BnZbAg":55,"$f5rN7OgsUKzO1_ML-Mzl6yGvnLBWzxarfhGzZJWsBKUA":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},68620,870962,[],"https://cdn.yishi-tong.com/console/store-unknown/uF7OMd0P_hB1LaAPsAH23kXFsYY6stA4.png","冯国清","海宁市中医院","普外科","主任医师",4,0,"用于乳腺癌治疗的常用化疗药物实用药指南","","https://ystcdn.venuertc.com/venue/AI/8b48a067-100a-4491-b38c-7d6ba6cd82c4.jpg","\u003Cdiv class=\"material-article-box\">\n  \u003C!-- 文章主标题 -->\n  \u003Ch1 class=\"material-main-title\" id=\"material_title\">用于乳腺癌治疗的常用化疗药物实用药指南\u003C/h1>\n  \n  \u003C!-- 开头引入 -->\n  \u003Cdiv class=\"material-intro\">\n    在化疗药物的众多组合中，通过静脉滴注应用的抗肿瘤药物如紫杉醇、多柔比星、环磷酰胺等，都是医疗实践中的主角。这类药品针对乳腺癌的治疗被广泛应用，但不管是哪种药，每一步操作和注意事项都和疗效、风险息相关。今天，我们就来详细拆解乳腺癌治疗常见化疗药物的7个关键用药细节，让安全与效果兼得。\n  \u003C/div>\n  \n  \u003C!-- 01 剂型与给药方式 -->\n  \u003Csection class=\"material-section\" style=\"background:linear-gradient(135deg,#e8eefa 20%,#f8f8ff 100%)\">\n    \u003Ch2 class=\"material-section-title\">01 剂型与给药方式 💉\u003C/h2>\n    \u003Cdiv class=\"material-section-content\">\n      目前临床常用的抗肿瘤药物如紫杉醇（Paclitaxel）、多柔比星（Doxorubicin）、环磷酰胺（Cyclophosphamide）主要以注射液或冻干粉剂型出现，全部通过静脉滴注或静脉注射方式给药。正确做法：药物需严格按照药师或医生提供的操作流程配制，完全溶解后再进全静脉滴注，输注过程严禁私自调整速度。静脉通道保持通畅非常关键，避免药液渗漏至皮下引发局部组织坏死。\u003Cbr>\n      特别提醒：不可将这类药品与肌肉注射或皮下注射方式混用，也不能直接口服。\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 02 服药时间与疗程布局 -->\n  \u003Csection class=\"material-section\" style=\"background:linear-gradient(135deg,#f9faf2 40%,#f7f8fd 100%)\">\n    \u003Ch2 class=\"material-section-title\">02 服药时间与疗程规划 ⏰\u003C/h2>\n    \u003Cdiv class=\"material-section-content\">\n      化疗药物的使用需严格遵循疗程周期。例如，第1天~第21天为一周期，每个周期内给药天数及间隔会根据医生定制调整。正确做法：务必按计划完成整个静脉给药周期，不能私自提前终止或推后。如果出现漏服，由专业人员评估补药或推迟方案。\u003Cbr>\n      案例提示：有位54岁女性患者，身高160cm，体重49kg，在静脉滴注化疗药物时，严格遵守每日一次的用法，保证药物达到稳定的血药浓度，为治疗提供保障。\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 03 药物作用机制速览 -->\n  \u003Csection class=\"material-section\" style=\"background:linear-gradient(135deg,#fff6ef 30%,#eeeeff 100%)\">\n    \u003Ch2 class=\"material-section-title\">03 主要作用机制 🧬\u003C/h2>\n    \u003Cdiv class=\"material-section-content\">\n      紫杉醇：可阻断肿瘤细胞有丝分裂，使细胞停滞在有丝分裂期。\u003Cbr>\n      多柔比星：嵌入DNA分子，抑制DNA合成，产生细胞毒性作用。\u003Cbr>\n      环磷酰胺：为烷化剂类药物，与DNA发生交联，阻止细胞分裂。\u003Cbr>\n      正确做法：患者本身不需过度关注作用细节，但了解药物是通过影响肿瘤细胞增殖来起效，有助于理解规范用药的重要性。\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 04 用法用量的关键要求 -->\n  \u003Csection class=\"material-section\" style=\"background:linear-gradient(135deg,#f2f8f5 24%,#fdeff9 100%)\">\n    \u003Ch2 class=\"material-section-title\">04 用法用量的关键要求 ⚖️\u003C/h2>\n    \u003Cdiv class=\"material-section-content\">\n      化疗药物的具体剂量通常按体表面积（m²）或体重（kg）来个体化计算。例如，紫杉醇常用剂量每平方米175mg，多柔比星按每平方米60-75mg调整。绝不能自行增减剂量或改变用药天数，否则可能导致疗效下降或副作用增加。服用前需确认近期血常规、肝肾功能等指标在安全范围。\n      \u003Cul>\n        \u003Cli>\u003Cb>输注时间：\u003C/b>紫杉醇等注射液通常要求缓慢输注（>3小时），多柔比星输注不宜过快。\u003C/li>\n        \u003Cli>\u003Cb>间隔要求：\u003C/b>多种化疗药品在一个周期内顺序输注时，遵从临床配伍顺序。\u003C/li>\n      \u003C/ul>\n      需要注意：如遇特殊体质、老年患者或体重偏低者，剂量可能需下调。\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 05 常见药物相互作用及影响 -->\n  \u003Csection class=\"material-section\" style=\"background:linear-gradient(135deg,#f4f9f2 15%,#ffffff 100%)\">\n    \u003Ch2 class=\"material-section-title\">05 药物相互作用 ⚠️\u003C/h2>\n    \u003Cdiv class=\"material-section-content\">\n      化疗药物与其他药品之间有较高的相互作用风险。\u003Cbr>\n      \u003Cul>\n        \u003Cli>\n          \u003Cspan class=\"material-li-title\">与细胞毒性药物联合：\u003C/span>\n          普遍按方案分层给药，但药物间可能相互增强骨髓抑制作用。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"material-li-title\">与CYP3A4酶抑制剂或诱导剂：\u003C/span>\n          如酮康唑、利福平等，会影响紫杉醇的代谢，需避免与此类药同服。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"material-li-title\">与心脏药物：\u003C/span>\n          多柔比星会增强心脏毒性风险，合用需严密监测。\n        \u003C/li>\n      \u003C/ul>\n      正确做法：用药前主动告知医生自己当前和近期使用的所有药物，避免药物间发生不可预知的相互作用。无需自行增减任何伴随药品。\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 06 主要不良反应与处理建议 -->\n  \u003Csection class=\"material-section\" style=\"background:linear-gradient(135deg,#f6f9ee 36%,#fff6f9 100%)\">\n    \u003Ch2 class=\"material-section-title\">06 常见不良反应及处理 👀\u003C/h2>\n    \u003Cdiv class=\"material-section-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cspan class=\"material-li-title\">骨髓抑制：\u003C/span>\n          以白细胞、红细胞及血小板计数下降为主。一般在用药后7-14天出现，中性粒细胞减少最常见。处理方式：用药前和用药后需定期监测血常规。严重时由医师根据情况给予升白针或暂停化疗。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"material-li-title\">消化道反应：\u003C/span>\n          包括恶心、呕吐、食欲减退等。给予止吐药支持、分餐饮食可缓解。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"material-li-title\">脱发（紫杉醇、环磷酰胺更为普遍）：\u003C/span>\n          虽然影响形象但一般为可逆，治疗结束后头发会逐步再生。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"material-li-title\">静脉炎或渗漏：\u003C/span>\n          部分药物外渗后引发局部炎症与坏死，需专业处理。一旦发生红、肿等异常即刻报告医护人员。\n        \u003C/li>\n      \u003C/ul>\n      临床研究数据显示，紫杉醇相关骨髓抑制发生率可达90%左右，多柔比星可见心脏毒性比率在7%-26%（Swain, S. M., Whaley, F. S., & Ewer, M. S., 2003）。化疗期间任何明显不适均应及时反馈专业人员。\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 07 特殊人群用药注意事项 -->\n  \u003Csection class=\"material-section\" style=\"background:linear-gradient(135deg,#eff9f2 10%,#f2f3fc 100%)\">\n    \u003Ch2 class=\"material-section-title\">07 特殊人群用药指导 🧑‍🦳👩‍🍼\u003C/h2>\n    \u003Cdiv class=\"material-section-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cspan class=\"material-li-title\">老年人：\u003C/span>\n          基础代谢下降，耐受性较差，需个体化调整剂量，紧密监控副作用。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"material-li-title\">肝肾功能不全：\u003C/span>\n          多柔比星及紫杉醇主要经肝脏代谢，肝功能异常或胆红素升高时应减少剂量或更换药品。环磷酰胺需注意肾功能指标。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"material-li-title\">妇女妊娠及哺乳期：\u003C/span>\n          这类药品多为胚胎毒性及致畸风险，孕妇禁止用于任何化疗药物。哺乳期如果必须用药应暂停哺乳。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"material-li-title\">儿童：\u003C/span>\n          用药须严格权衡风险与收益，始终遵照专业儿科肿瘤医师给定的个体化方案。\n        \u003C/li>\n      \u003C/ul>\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 08 储存、有效期与药品管理 -->\n  \u003Csection class=\"material-section\" style=\"background:linear-gradient(135deg,#fcf8ef 10%,#eef3f9 100%)\">\n    \u003Ch2 class=\"material-section-title\">08 药品储存及有效期 📦\u003C/h2>\n    \u003Cdiv class=\"material-section-content\">\n      抗肿瘤注射剂需在2-8℃冷藏，避光保存，不得冷冻。开瓶后剩余药品应立即丢弃，严禁保存以备下次重复使用。冻干粉需在规定时间内配好并尽快使用，溶液滴注过程中如发现变色、沉淀、异味，需立即更换。\u003Cbr>\n      案例补充：曾遇一位患者，忘记及时丢弃剩余的化疗药液，结果因药品变质导致局部输液反应。正确做法：剩药不留存，开瓶后当次用完是底线。\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 09 漏服及过量应对 -->\n  \u003Csection class=\"material-section\" style=\"background:linear-gradient(135deg,#f9f6fb 45%,#f5f8f7 100%)\">\n    \u003Ch2 class=\"material-section-title\">09 漏服和过量的科学应对 \u003C/h2>\n    \u003Cdiv class=\"material-section-content\">\n      漏服：化疗药物若漏服某一次，应在专业人员评估后重新规划补药方案。禁止自行直接加倍补用，以免毒性叠加。\u003Cbr>\n      过量：一旦出现超量使用（意外重复用药或剂量计算失误），应紧急就医，医生会根据症状对症处理，包括强化生命体征监测和应用解毒药支持等。未出现任何不适症状时也不要自作主张拖延就诊。\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 结尾总结/安全提醒 -->\n  \u003Cdiv class=\"material-summary material-boxline\">\n    总结来说，乳腺癌患者常用的化疗药物如紫杉醇、多柔比星、环磷酰胺等，每一步用法细节都对疗效和安全有直接影响。\u003Cspan class=\"material-important\">最重要的两点：\u003C/span>第一，必须全程在医护人员指导下规范输注和管理药品；第二，绝不要漏服、补服或自行调整任何细节。治疗期间遇到不适、疑问或意外情况时，主动沟通专业人员始终是最稳妥的做法。\n  \u003C/div>\n  \n  \u003C!-- 参考文献 -->\n  \u003Cdiv class=\"material-references\">\n    \u003Ch3 class=\"material-reference-title\">References\u003C/h3>\n    \u003Col>\n      \u003Cli>Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003). Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. \u003Ci>Cancer\u003C/i>, 97(11), 2869-2879. https://doi.org/10.1002/cncr.11407\u003C/li>\n      \u003Cli>Bernard-Marty, C., et al. (2004). Safety and efficacy of taxane therapy for advanced breast cancer: a meta-analysis of randomized trials. \u003Ci>Journal of Clinical Oncology\u003C/i>, 22(26), 5110-5120. https://doi.org/10.1200/JCO.2004.01.111\u003C/li>\n      \u003Cli>DeVita, V. T., & Chu, E. (2008). A history of cancer chemotherapy. \u003Ci>Cancer Research\u003C/i>, 68(21), 8643-8653. https://doi.org/10.1158/0008-5472.CAN-07-6611\u003C/li>\n    \u003C/ol>\n  \u003C/div>\n\u003C/div>\n\n\u003Cstyle>\n.material-article-box {\n  font-family: \"Helvetica Neue\", Arial, \"PingFang SC\", \"Microsoft YaHei\", sans-serif;\n  background-color: #fc;\n  max-width: 840px;\n  margin: 30px auto 40px auto;\n  padding: 36px 30px 30px 30px;\n  border-radius: 18px;\n  box-shadow: 0 6px 32px rgba(90,120,150,0.06), 0 1.5px 3px rgba(80,110,180,0.02);\n  color: #333;\n  min-height: 1250px;\n  box-sizing: border-box;\n}\n\n.material-main-title {\n  font-size: 2.2em;\n  font-weight: bold;\n  color: #1e3658;\n  margin-bottom: 24px;\n  line-height: 1.28;\n  letter-spacing: 1.2px;\n  text-align: center;\n  background: linear-gradient(to right, #eaf6ff 10%, #fdf3ee 90%);\n  padding: 22px 8px 18px 8px;\n  border-radius: 10px;\n}\n\n.material-intro {\n  font-size: 1.16em;\n  color: #41507a;\n  background: linear-gradient(120deg,#eef5ff 80%, #fef5ed 100%);\n  padding: 18px 24px 18px 24px;\n  border-radius: 10px;\n  margin-bottom: 32px;\n  line-height: 1.9;\n  box-shadow: 0 1px 5px rgba(120,150,200,0.04);\n  letter-spacing: 1px;\n}\n\n.material-section {\n  padding: 34px 22px 30px 22px;\n  border-radius: 13px;\n  margin-bottom: 28px;\n  box-shadow: 0px 3px 9px rgba(180,185,210,0.04);\n  transition: box-shadow 0.3s;\n}\n.material-section:hover {\n  box-shadow: 0px 5px 22px rgba(80,130,180,0.12);\n}\n.material-section-title {\n  font-size: 1.45em;\n  font-weight: bold;\n  color: #224d63;\n  margin-bottom: 15px;\n  padding-left: 8px;\n  line-height: 1.32;\n  letter-spacing: 1px;\n  text-shadow: 0 1px 1px #fafdff,0 0.5px 0 #e9eaf2;\n  display: flex;\n  align-items: center;\n  gap: 9px;\n  padding-bottom: 6px;\n}\n\n.material-section-content {\n  font-size: 1.09em;\n  color: #33394a;\n  line-height: 2.0;\n  letter-spacing: 0.14em;\n  padding-left: 3px;\n}\n\n.material-section-content ul {\n  list-style: disc;\n  margin-left: 21px;\n  margin-bottom: 8px;\n}\n.material-li-title {\n  color: #1458a5;\n  font-weight: 500;\n}\n.material-boxline {\n  border-left: 5px solid #80b9f0;\n  background: linear-gradient(to right,#eef5fd 92%,#f7fafd 100%);\n  padding: 19px 24px 19px 16px;\n  border-radius: 8px;\n  margin-top: 20px;\n  margin-bottom: 22px;\n  font-size: 1.12em;\n  color: #2c4158;\n  line-height: 1.82;\n}\n.material-important {\n  color: #e97c13;\n  font-weight: bold;\n  padding-left: 5px;\n  padding-right: 3px;\n  letter-spacing: 1px;\n}\n.material-references {\n  margin-top: 35px;\n  margin-bottom: 4px;\n  background: linear-gradient(90deg, #f0f5fb 85%, #faf9ef 100%);\n  padding: 20px 26px 14px 24px;\n  border-radius: 8px;\n  color: #223b53;\n}\n.material-reference-title {\n  font-size: 1.06em;\n  font-weight: 600;\n  border-left: 4px solid #aac8df;\n  padding-left: 9px;\n  margin-bottom: 10px;\n  color: #183758;\n}\n.material-references ol {\n  padding-left: 18px;\n  font-size: 1em;\n}\n.material-references li {\n  margin-bottom: 9px;\n  line-height: 1.77;\n}\n@media (max-width: 650px) {\n  .material-article-box {padding: 8vw 1.5vw 6vw 1.5vw; min-width: 0;}\n  .material-main-title {font-size: 1.2em;}\n  .material-section {padding: 17px 4vw 11px 3vw;}\n  .material-intro {font-size: 1em;}\n}\n\u003C/style>","\u003Cdiv class=\"material-article-box\">\n  \u003C!-- 文章主标题 -->\n  \u003Ch1 class=\"material-main-title\" id=\"material_t",518,"2025-10-28 00:12:15","乳腺癌, 化疗药物, 紫杉醇, 多柔比星, 环磷酰胺, 药物使用指南, 抗肿瘤药物, 用药安全","本指南深入解析乳腺癌患者使用化疗药物如紫杉醇、多柔比星的7个关键细节，助您安全有效用药，掌握疗效与风险。适合乳腺癌患者、家属及医护人员。","2025-11-18 14:56:21",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]